Servier Innovative Drug Project to Launch in TEDA

From November 2 to 7, Zhang Gong, Mayor of Tianjin, led a municipal government delegation on visits to France and Italy. The delegation visited enterprises, attended promotional exchange meetings for Tianjin, and expanded practical cooperation in areas such as economic and trade investment, sister-city exchanges, and cultural tourism exhibitions.

During this visit, the TEDA Administrative Commission and Servier (Tianjin) Pharmaceutical Co., Ltd. held a signing ceremony at Servier's headquarters in France. Servier's innovative drug project, Vorasidenib, will officially be established in TEDA. With an investment of hundreds of millions of yuan, the project plans to produce Voranigo, an innovative drug newly developed by Servier for the treatment of glioma. This drug is the world's first targeted therapy for astrocytoma or oligodendroglioma with IDH1/2 mutations, applicable to adult and pediatric patients aged 12 and above. Its is projected to achieve annual sales of 1 billion yuan after hitting the market.

Servier Pharmaceuticals, headquartered in Suresnes, France, focuses on four key therapeutic areas: cardiovascular and metabolic diseases, oncology, neuroscience, and immunoinflammatory diseases. Its product portfolio covers over 20 medical specialties, and the company operates in 140 countries.